Skip to main content

Imaging

Bimekizumab Maintains Improvements in Efficacy Endpoints and has a Consistent Safety Profile Through 52 Weeks in Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis: Results from Two Parallel Phase 3 Studies

Sponsored by UCB
Mar 09, 2023

This poster reports key efficacy outcomes such as ASAS40 response at Week 16 and Week 52 for the overall population and in TNFi-naïve and TNFi-experienced patients. The poster also discusses patients treated with BKZ achieving low disease activity (LDA) based on the ASDAS scores, objective

Read Article

Without DMARDS, Shoulder Arthroplasty Increasing in Rheumatoid Arthritis

Feb 09, 2023

The need for total shoulder arthroplasty (TSA) in rheumatoid arthritis (RA) patients appears to depend on the use of disease modifying antirheumatic drugs (DMARDs), according to Seminars in Arthroplasty.

Read Article
GRAPPA Recommendations for Treating Enthesitis in PsA GRAPPA has provided new updates to the mgmt of enthesitis in patients with PsA, affecting at least 30% of PsA patients and is associated with more severe disease, x-ray damage, and poorer outcomes. https://t.co/AC6KHGMeo0

Burnout #10 (2.3.2023)

Feb 03, 2023

Dr. Jack Cush reviews the past week of news on RheumNow.com.

Read Article

Novel Proteomic Biomarker Set in Osteoarthritis

Feb 02, 2023

NIH funded researchers from Duke University have developed a set of serum proteomic biomarkers that successfully predict clinically relevant knee osteoarthritis (KOA) progression (both structural change and joint pain) over a 2 year period.

Read Article

Women at high risk of fracture remain untreated for osteoporosis

EurekAlert!
Jan 30, 2023

An estimated 100,000 to 120,000 fragility fractures occur annually in the Netherlands, the equivalent of at least 11 broken bones per hour. The cause is osteoporosis, a disease in which the skeleton becomes weak and fragile, leading to potentially devastating fractures that result in

Read Article

Simon Says “Don’t Do This” (1.27.2022)

Jan 27, 2023

Dr. Jack Cush reviews this week’s journal articles, focuses on studies that should not have been done and responds to viewer questions in Ask Cush Anything.




  1. "Dry Synovitis" exist in juvenile arthritis pts? Study of 12 DS pts, says its different from Poly #JIA; onset 6.1 yrs

Read Article

Blood Test Identifies Osteoarthritis Progression

EurekAlert!
Jan 25, 2023

A new blood test that can identify progression of osteoarthritis in the knee is more accurate than current methods, providing an important tool to advance research and speed discovery of new therapies.



The test relies on a biomarker and fills an important void in medical research for

Read Article

PsA Til Death Do Us Part (1.20.2023)

Jan 20, 2023

Dr. Jack Cush reviews the highlights from the past week on RheumNow.com.

Read Article

Phase III Trials Back Bimekizumab for Spondyloarthritis

Medpage Today
Jan 19, 2023

Bimekizumab, an investigational biologic drug targeting interleukin (IL)-17A/F, appeared highly effective in patients with axial spondyloarthritis (axSpA), researchers said.

Read Article

Poorer health outcomes for at-risk patients with fractures

Jan 18, 2023

People at high risk of fracture who also have complex or multiple chronic medical conditions are less likely to receive treatment for the underlying osteoporosis and also have poorer health outcomes, according to a new study from the Garvan Institute of Medical Research.  



These

Read Article

Best of 2022: New Updated GRAPPA Psoriatic Arthritis Recommendations

Dec 26, 2022

The GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) treatment recommendations have been updated and the 2021 evidence-based guidance is rich in treatment recommendations based on the key disease "domains" - peripheral arthritis, axial disease, enthesitis,

Read Article

JAK Inhibitor Potential in Systemic Sclerosis-Associated ILD

Dec 15, 2022

The occurrence of interstitial lung disease (ILD) in Systemic sclerosis portends serious morbid and mortal outcomes for those affected. This review examines the available clinical literature on the potential benefits and outcomes of JAK inhibitor use in SSc=ILD.



Overall the authors

Read Article

Substandard Therapy in Rheumatoid Arthritis

Medpage Today
Dec 13, 2022

Clinicians could improve outcomes in their patients with rheumatoid arthritis (RA) by paying attention to certain markers of care quality, such as early referral to certified rheumatologists and prescribing standard drugs for RA, new research suggested.

Read Article

2022 ACR/EULAR Giant Cell Arteritis Classification Criteria

Dec 12, 2022

Giant cell arteritis (GCA) has historically been a clinical diagnosis (visual loss, headache, jaw pain, scalp tenderness, etc) supported by labs and histopathology. Yet the diagnosis and classification of GCA has evolved, so much so that the ACR and EULAR have updated the 1990 Classification

Read Article

RECITAL Trial: RTX vs. CTX in CTD-ILD

Dec 01, 2022

A UK study suggests the equivalent outcomes when patients with interstitial lung disease (ILD) associated with connective tissue disease (CTD) are treated with either intravenous rituximab (RTX) or cyclophosphamide (CTX), but with fewer adverse events with RTX. 

Read Article

How Underweight Women Can Reduce Hip Fracture Risk

EurekAlert!
Nov 28, 2022

How women can reduce the risk of hip fracture?  

Read Article
Open label trial compared arthroscopic repair to PT in 100 young pts w/ traumatic, MRI proven meniscal tear without knee OA. Outcomes at 24 months - both groups improvved and were not different between groups https://t.co/rbrUAWuKRa https://t.co/OaNTssAvCG

The disconnect between objective inflammatory response and PROs in AxSpA

Nov 23, 2022

The assessment of disease activity in AxSpA involves the use of objective inflammatory response (OIR) and patient reported outcomes (PROs). In clinics, a combination of OIR and PROs are used to measure disease activity and response to treatment. OIR includes measurements such as CRP and MRI

Read Article

Imaging in PMR

Nov 18, 2022

Despite the fact that polymyalgia rheumatica is the most prevalent inflammatory rheumatic disease in those over 65 years of age, progress in its diagnosis, monitoring and management have failed to garner momentum in decades past.

However, ACR22 has fostered significant promise for its future.

Read Article
van Nieuwland et al. Comparison US/PET/MRI in GCA. Good specificity but relatively low sensitivity for all. PET best for extra-cranial. MRI/US best for isolated cranial. @RheumNow #ACR22 Abstr#1617 https://t.co/CI3TtxOQJL https://t.co/3pJeGo49Gj
Spinal lesions on MRI in axSpA is ~3% in patients with negative imaging in SIJ on MRI or X-ray. Agreement in >5/9 central readers. Frequency of spinal vertebral corner BME lesions was significantly higher these cases. Maksymovych Abs#2257 https://t.co/56yxGxBgLp #ACR22 @RheumNow https://t.co/CkJ9o2dJuT

ACR Best Abstracts - Day 2

Nov 13, 2022

Day two at ACR 2022 was full of great sessions on imaging, vasculitis, lupus, vasculitis, spondyloarthritis, COVID, pregnancy, microbiome, economics and more.

Here are the RheumNow faculty selections for #ACRbest abstracts today:

Read Article

Can Neural Networks Answer Important Diagnostic Dilemmas in Rheumatology?

Nov 13, 2022

An interesting study presented at ACR22 looked at whether neural networks can distinguish seropositive rheumatoid arthritis (RA+), seronegative RA (RA-), and psoriatic arthritis (PsA) using hand MRI data based on the structural inflammation patterns.

Read Article
De Craemer et al. Local vs Central reading of images. Rheumatologists overcall sacroiliitis on both plain films and MRI in ?AxSpA . ? some of this out of a desire to try something to help someone who is suffering @RheumNow #ACR22 Abstr#1255 https://t.co/j89E0sUPmN https://t.co/Ez5ldSSQJl
×